November 12, 2020
Medicare to cover monoclonal antibody COVID-19 treatments
Editor's Note
The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency.
The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug Administration.
Medicare won’t pay for monoclonal antibody products that providers receive for free, but it will pay for the infusion.
Free Daily News
- Kentucky Derby, SPD race: Leadership lessons energized SPD professionals at HSPA 2025
- Continuum-based protocol offers new strategy for preventing PONV after thyroidectomy
- Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
- Subarachnoid spinal anesthesia offers safe, effective option for high-risk obstetric patients
- Same-day discharge after catheter ablation gains backing from top cardiology societies
- Tenet, HCA post strong Q1 results, but caution looms over policy uncertainty, outpatient trends
- Telemedicine transforms postoperative care through safer, faster, patient-centered recovery
- ASCA conference coverage to keep ASC leaders informed
- Study: Prolonged COVID symptoms more likely for healthcare workers
- Study: Patients of female surgeons experience fewer complications, lower long-term readmission
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement